As Attomarker enters its next phase of development, we have announced that the company is undertaking an Acceleration Round. For many people, the term itself can sound abstract or overly financial, so we felt it worth explaining plainly what it means in practice, and just as importantly, what it does not.
An Acceleration Round is not a change in direction, and Attomarker remains passionate about the patients and clinicians it serves. It is an addition of capability, building on foundations that are already in place.
For Attomarker, this stage reflects the point at which ongoing scientific, clinical, and validation work is joined by a more structured phase of commercial rollout and operational support. It is very much an and, not an or. We are not changing one thing for another.
What motivates this stage for us is simple: the desire to ensure that work we believe in can reach more clinicians, and ultimately more patients, in a way that is reliable, responsible, and sustainable. This is what we set out to do and the launch of the Acceleration Round marks the next foot forward in that mission.
From proof to execution, without leaving proof behind
In the early life of a diagnostics company, much of the work is necessarily inward-focused. The emphasis is on scientific validation, technical performance, regulatory readiness, and ensuring that what is being built actually works as intended.
That work does not stop at an Acceleration Round.
Reaching this stage signals that those foundations are sufficiently established to support the next layer of activity: ensuring that validated diagnostics can be deployed, supported, and extended responsibly in real clinical environments, at greater scale.
Scientific validation, clinical evidence generation, and regulatory discipline continue. What changes is that they are no longer happening in isolation, but alongside more deliberate commercial and operational structures that allow the work to be shared more widely.
This matters because good science only fulfils its purpose when it is accessible, understood, and used well.
What “acceleration” actually refers to
Acceleration in this context does not mean rushing, nor does it mean reducing scientific rigour, something we have consistently called for.
It refers to putting the necessary functions on a commercial footing rather than a start-up footing. That means taking what would be bottlenecks to commercial roll out and ensuring they function as we scale.
In early stages, many constraints are managed through small teams, informal processes, and limited resources. It’s what a start-up really is. That is appropriate, and often unavoidable. But it also places natural limits on reach, resilience, and consistency.
At this stage, acceleration means addressing those limits thoughtfully, including:
- supporting and expanding clinical deployment while maintaining quality and interpretation
- progressing regulatory and compliance activity in a systematic, repeatable way
- strengthening clinical validation and evidence generation as deployment grows
- building operational resilience, governance, and support functions
- extending an existing diagnostic portfolio in a controlled, disciplined manner
These activities are not speculative. They are about making validated work usable, sustainable, and trustworthy at scale, so that clinicians and patients experience the same consistency at scale that they have come to expect when managed very personally in a more limited form.
What this stage is not
It is equally important to be clear about what an Acceleration Round is not.
It is not a pivot away from scientific or clinical validation.
It is not a substitution of evidence with marketing.
It is not a promise of rapid outcomes or simplified answers.
Diagnostics, particularly in immune-mediated disease, require ongoing evidence, careful interpretation, and continual refinement. It’s a continuous journey of discovery, application of new learning and even re-thinking principles as new evidence emerges. Those requirements increase rather than diminish as diagnostics move into broader use.
As reach grows, so does responsibility.
Why this matters now
For Attomarker, this moment reflects maturity rather than novelty.
The work ahead is about holding two things together at the same time:
- continuing to generate and strengthen clinical evidence, and
- ensuring that the systems around that evidence are capable of supporting real-world use
This is the difference between a promising diagnostic tool and one that clinicians can rely on, integrate into practice, and discuss openly with patients.
Being able to reach and help more people does not come from ambition alone. It comes from doing the unglamorous work properly: support, training, governance, evidence, and responsiveness. Alongside greater reach, these are the true targets or use of funds coming from the Acceleration Round.
Looking ahead
An Acceleration Round marks a phase where the emphasis is on doing more of what already works, more reliably and more broadly, rather than changing course.
It is about reinforcing scientific foundations while adding the commercial, operational, and regulatory structures required for sustained clinical impact.
There is a sense of momentum at this stage, but it is grounded momentum. The excitement comes not from speed, but from the possibility of serving more clinicians and patients without compromising the values and care that shaped the work in the first place.
Those priorities define what acceleration means for Attomarker at this point in its journey.
Important Note
Retail investor participation is being conducted through Crowdcube, which is authorised and regulated by the Financial Conduct Authority. All eligibility checks, approvals, and investment activity take place on the Crowdcube platform.
https://www.crowdcube.com/early-access/attomarker
Information for non-retail investors is available via a separate information page.
https://attomarker.com/investors/
This announcement is provided for information purposes only and does not constitute an offer, solicitation, or invitation to invest.